Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.72 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.72 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.72 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.72 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.72 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.70 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.63 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14928757 | 1.00 | P2RY1 (0.72) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL14948858 | 1.00 | P2RY1 (0.72) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL19442379 | 1.00 | P2RY1 (0.72) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL14853693 | 1.00 | P2RY1 (0.72) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL625113 | 1.00 | P2RY1 (0.72) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL309060 | 0.99 | P2RY1 (0.71) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL18950213 | 0.94 | P2RY1 (0.63) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL17010791 | 0.92 | CA5A (0.67) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL263421 | 0.92 | CA5A (0.67) | P2RY1P2RX3ENPP1P2RY11P2RX1 | |
| SCHEMBL15071495 | 0.92 | CA5A (0.67) | P2RY1P2RX3ENPP1P2RY11P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931319-B1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10258698-B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | MODERNATX, INC. (US) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258698-B2 | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions | NSUN2, RNMT, ADAR | P2RY1 1666/4885P2RX3 2793/4885ENPP1 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.